Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Shantha Biotechnics - the Indian biotech acquired by Sanofi-Aventis - has bagged a $340 million contract from the World Health Organization for supply of the pentavalent vaccine branded SHAN5 over a period of two years starting 2010. The vaccine indigenously developed by Shantha immunizes children against diphtheria, pertussis, tetanus, hemophillus influenza B and hepatitis B
Advertisement

Related Content

India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal
India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
Advertisement
UsernamePublicRestriction

Register

SC072929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel